Increasing Mortality in the United States from Cholangiocarcinoma: an Analysis of the National Center for Health Statistics Database

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2016 Sep 23

PMID 27655244

Citations 58

Authors

Kaelan J Yao

Salma Jabbour

Niyati Parekh

Yong Lin

Rebecca A Moss

Affiliations

Soon will be listed here.

Abstract

Background: While mortality in the United States has decreased for most cancers, mortality from combined hepatocellular liver cancer and intrahepatic cholangiocarcinoma (ICC) has increased and ranked 1st in annual percent increase among cancer sites. Because reported statistics combine ICC with other liver cancers, mortality rates of cholangiocarcinoma (CCA) remain unknown. This study is to determine CCA mortality trends and variation based on national data.

Methods: This nation-wide study was based on the underlying cause of death data collected by the National Center for Health Statistics (NCHS) between 1999 and 2014. The Center for Disease Control (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) system was used to obtain data. ICC and extra-hepatic CCA (ECC) were defined by ICD-10 diagnosis codes. Age-adjusted mortality rate was standardized to the US population in 2000.

Results: There were more than 7000 CCA deaths each year in the US after 2013. CCA mortality for those aged 25+ increased 36 % between 1999 and 2014, from 2.2 per 100,000 (95 % confidence interval [CI] 2.1-2.3) to 3.0 per 100,000 (95 % CI, 2.9-3.1). Mortality rates were lower among females compared with males (risk ratio [RR] 0.78, 95 % CI 0.77-0.79). Asians had the highest mortality. Between 2004 and 2014, the increase in CCA mortality was highest among African Americans (45 %) followed by Asians (22 %), and whites (20 %).

Conclusion: Based on the most recent national data, CCA mortality rates have increased substantially in the past decade. Among different race/ethnic groups, African Americans have the highest increase in CCA mortality.

Citing Articles

Sever N, Yunusov E, Majidova N, Kocaaslan E, Erel P, Agyol Y J Cancer Res Clin Oncol. 2025; 151(2):95.

PMID: 40016575 PMC: 11868355. DOI: 10.1007/s00432-025-06096-y.

Age and Tumor Stage Interplay in Intrahepatic Cholangiocarcinoma: Prognostic Factors, Mortality Trends, and Therapeutic Implications from a SEER-Based Analysis.

Bangolo A, Nagesh V, Tran H, Sens B, Elias D, Amoozgar B Diseases. 2025; 13(2).

PMID: 39997038 PMC: 11854301. DOI: 10.3390/diseases13020031.

Cystatin B Promotes the Proliferation, Migration, and Invasion of Intrahepatic Cholangiocarcinoma.

Zhang D, Sun B, Wu J, Wang Z, Zheng S, Sun G Curr Oncol. 2025; 32(2).

PMID: 39996856 PMC: 11854580. DOI: 10.3390/curroncol32020056.

Digestive cancers: mechanisms, therapeutics and management.

Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M Signal Transduct Target Ther. 2025; 10(1):24.

PMID: 39809756 PMC: 11733248. DOI: 10.1038/s41392-024-02097-4.

Cognitive and ataxic adverse events following entrectinib treatment in NTRK1 fusion gene-positive intrahepatic cholangiocarcinoma: a case report.

Koyama K, Iwamoto H, Takahashi K, Okada T, Kawabata H, Kitano Y Clin J Gastroenterol. 2024; 18(1):183-187.

PMID: 39644450 DOI: 10.1007/s12328-024-02076-w.

References

Aranha G, Reyes C, GREENLEE H, Field T, Brosnan J . Squamous cell carcinoma of the proximal bile duct--a case report. J Surg Oncol. 1980; 15(1):29-35. DOI: 10.1002/jso.2930150106. View

Hirschfield G, Karlsen T, Lindor K, Adams D . Primary sclerosing cholangitis. Lancet. 2013; 382(9904):1587-99. DOI: 10.1016/S0140-6736(13)60096-3. View

Nordenstedt H, Mattsson F, El-Serag H, Lagergren J . Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma. Br J Cancer. 2012; 106(5):1011-5. PMC: 3305961. DOI: 10.1038/bjc.2011.607. View

McLean L, Patel T . Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int. 2006; 26(9):1047-53. DOI: 10.1111/j.1478-3231.2006.01350.x. View

Nakeeb A, Pitt H, Sohn T, Coleman J, Abrams R, Piantadosi S . Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224(4):463-73; discussion 473-5. PMC: 1235406. DOI: 10.1097/00000658-199610000-00005. View

Groot Koerkamp B, Fong Y . Outcomes in biliary malignancy. J Surg Oncol. 2014; 110(5):585-91. DOI: 10.1002/jso.23762. View

Welzel T, Graubard B, El-Serag H, Shaib Y, Hsing A, Davila J . Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5(10):1221-8. PMC: 2083573. DOI: 10.1016/j.cgh.2007.05.020. View

Khan S, Emadossadaty S, G Ladep N, Thomas H, Elliott P, Taylor-Robinson S . Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol. 2011; 56(4):848-54. DOI: 10.1016/j.jhep.2011.11.015. View

Shin H, Oh J, Masuyer E, Curado M, Bouvard V, Fang Y . Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010; 101(3):579-85. PMC: 11158235. DOI: 10.1111/j.1349-7006.2009.01458.x. View

10.

Welzel T, Graubard B, Zeuzem S, El-Serag H, Davila J, McGlynn K . Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54(2):463-71. PMC: 4141525. DOI: 10.1002/hep.24397. View

11.

Ribero D, Nuzzo G, Amisano M, Tomatis M, Guglielmi A, Giulini S . Comparison of the prognostic accuracy of the sixth and seventh editions of the TNM classification for intrahepatic cholangiocarcinoma. HPB (Oxford). 2011; 13(3):198-205. PMC: 3048972. DOI: 10.1111/j.1477-2574.2010.00271.x. View

12.

Chiu C, Chiang J, Yeh T, Tseng J, Chen T, Jan Y . Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?. Dig Liver Dis. 2008; 40(9):749-54. DOI: 10.1016/j.dld.2008.01.018. View

13.

Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T . Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci. 2004; 95(7):592-5. PMC: 11158843. DOI: 10.1111/j.1349-7006.2004.tb02492.x. View

14.

Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas H . Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; 37(6):806-13. DOI: 10.1016/s0168-8278(02)00297-0. View

15.

Altekruse S, Henley S, Cucinelli J, McGlynn K . Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542-53. PMC: 4148914. DOI: 10.1038/ajg.2014.11. View

16.

Lau K, Salami A, Barden G, Khawja S, Castillo D, Poppelaars V . The effect of a regional hepatopancreaticobiliary surgical program on clinical volume, quality of cancer care, and outcomes in the Veterans Affairs system. JAMA Surg. 2014; 149(11):1153-61. DOI: 10.1001/jamasurg.2014.1711. View

17.

Wise C, Pilanthananond M, Perry B, Alpini G, McNeal M, Glaser S . Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol. 2008; 14(19):2986-9. PMC: 2712163. DOI: 10.3748/wjg.14.2986. View

18.

Altekruse S, McGlynn K, Reichman M . Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27(9):1485-91. PMC: 2668555. DOI: 10.1200/JCO.2008.20.7753. View

19.

Ford E, Giles W, Dietz W . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3):356-9. DOI: 10.1001/jama.287.3.356. View

20.

Mao K, Jiang W, Liu J, Wang J . Incidence of subsequent cholangiocarcinomas after another malignancy: trends in a population-based study. Medicine (Baltimore). 2015; 94(8):e596. PMC: 4554149. DOI: 10.1097/MD.0000000000000596. View